Observational Registry of Basal Insulin Treatment (ORBIT) in Patients with Type 2 Diabetes Uncontrolled by Oral Hypoglycemic Agents in China - Study Design and Baseline Characteristics

Diabetes Technology and Therapeutics

Volumn 17, Issue 10, 2015, Pages 735-744

  Ji, Linong ^a,b   Zhang, Puhong ^b   Weng, Jianping ^c   Lu, Juming ^d   Guo, Xiaohui ^a   Jia, Weiping ^e   Yang, Wenying ^f   Zou, Dajin ^g   Zhou, Zhiguang ^h   Pan, Changyu ⁱ   Gao, Yan ^a   Li, Xian ^b   Zhu, Dongshan ^b   Li, Ying ^b   Wu, Yangfeng ^b   Garg, Satish K ^j  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^d CHINESE PLA GENERAL HOSPITAL   (China)

^e Shanghai 6th Hospital   (China)

^f CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^g SECOND MILITARY MEDICAL UNIVERSITY   (China)

^h CENTRAL SOUTH UNIVERSITY   (China)

ⁱ 301 Military General Hospital   (China)

^j UNIVERSITY OF COLORADO DENVER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLYCOSIDASE INHIBITOR; BASAL INSULIN; GLUCOSE; GLYCOSIDASE INHIBITOR; HEMOGLOBIN A1C; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; BODY WEIGHT; CEREBROVASCULAR ACCIDENT; CHINA; CONTROLLED STUDY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE DURATION; DISEASE REGISTRY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH CARE COST; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PERIPHERAL VASCULAR DISEASE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT DURATION; WEIGHT CHANGE; AGED; ANALYSIS; BLOOD; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; METHODOLOGY; MULTICENTER STUDY; REGISTER;

AGED; BLOOD GLUCOSE; CHINA; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; REGISTRIES; RESEARCH DESIGN;

EID: 84941369333     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2015.0054     Document Type: Article

References (41)

1. National Diabetes Research Group: A mass survey of diabetes mellitus in a population of 300,000 in 14 provinces and municipalities in China [in Chinese] (author's transl). Zhonghua Nei Ke Za Zhi 1981;20:678-683.
2. Yang W, Lu J, Weng J, et al.: Prevalence of diabetes among men and women in China. N Engl J Med 2010;362:1090-1101.
3. Gu D, Reynolds K, Duan X, et al.: Prevalence of diabetes and impaired fasting glucose in the Chinese adult population: International Collaborative Study of Cardiovascular Disease in Asia (InterASIA). Diabetologia 2003;46:1190-1198.
4. Pan XR, Yang WY, Li GW, et al.: Prevalence of diabetes and its risk factors in China, 1994. National Diabetes Prevention and Control Cooperative Group. Diabetes Care 1997; 20:1664-1669.
5. Xu Y, Wang L, He J, et al.: Prevalence and control of diabetes in Chinese adults. JAMA 2013;310:948-959.
6. Ali MK, Bullard KM, Gregg EW: Achievement of goals in U.S. diabetes care 1999-2010. N Engl J Med 2013;369: 287-288.
7. Ning G, Bloomgarden Z: Diabetes in China: prevalence, diagnosis, and control. J Diabetes 2013;5:372.
8. Ji LN, Lu JM, Guo XH, et al.: Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables. BMC Public Health 2013;13:602.
9. Li MZ, Su L, Liang BY, et al.: Trends in prevalence, awareness, treatment, and control of diabetes mellitus in Mainland China from 1979 to 2012. Int J Endocrinol 2013; 2013:753150.
10. Gale EA: Glucose control in the UKPDS: what did we learn? Diabet Med 2008;25(Suppl 2):9-12.
11. Kahn SE, Haffner SM, Heise MA, et al.: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-2443.
12. Cook MN, Girman CJ, Stein PP, et al.: Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care 2005;28:995-1000.
13. Steppel JH, Horton ES: Beta-cell failure in the pathogenesis of type 2 diabetes mellitus. Curr Diab Rep 2004;4:169-175.
14. Goudswaard AN, Stolk RP, Zuithoff P, et al.: Starting insulin in type 2 diabetes: continue oral hypoglycemic agents? A randomized trial in primary care. J Fam Pract 2004;53:393-399.
15. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977-986.
16. Mayfield JA, White RD: Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function. Am Fam Physician 2004;70:489-500.
17. Garber AJ, Abrahamson MJ, Barzilay JI, et al.: AACE comprehensive diabetes management algorithm 2013. Endocr Pract 2013;19:327-336.
18. Chinese Diabetes Society: China guideline for type 2 diabetes (2010). Chin J Front Med Sci (Electronic Version) 2011;03:54-109.
19. International Diabetes Federation 2012 Clinical Guidelines Task Force: Global Guideline for Type 2 Diabetes. 2012. www.idf.org/sites/default/files/IDF-Guideline-for-Type-2-Diabetes.pdf (accessed February 11, 2015).
20. Nathan DM, Buse JB, Davidson MB, et al.: Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203.
21. American Diabetes Association: Standards of medical care in diabetes-2014. Diabetes Care 2014;37(Suppl 1):S14-S80.
22. Meneghini LF, Rosenberg KH, Koenen C, et al.: Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Diabetes Obes Metab 2007;9:418-427.
23. Hamaty M: Insulin treatment for type 2 diabetes: when to start, which to use. Cleve Clin J Med 2011;78:332-342.
24. Curtis B, Lage MJ: Glycemic control among patients with type 2 diabetes who initiate basal insulin: a retrospective cohort study. J Med Econ 2014;17:21-31.
25. Ji L, Hu D, Pan C, et al.: Primacy of the 3B approach to control risk factors for cardiovascular disease in type 2 diabetes patients. Am J Med 2013;126:911-925.
26. Tsai ST, Pathan F, Ji L, et al.: First insulinization with basal insulin in patients with Type 2 diabetes in a real-world setting in Asia. J Diabetes 2011;3:208-216.
27. Ross S, Dzida G, Ji Q, et al.: Safety of once-daily insulin detemir in patients with type 2 diabetes treated with oral hypoglycemic agents in routine clinical practice. J Diabetes 2014;6:243-250.
28. Dailey G, Admane K, Mercier F, et al.: Relationship of insulin dose, A1c lowering, and weight in type 2 diabetes: comparing insulin glargine and insulin detemir. Diabetes Technol Ther 2010;12:1019-1027.
29. National Glycohemoglobin Standardization Program: List of NGSP Certified Methods. www.ngsp.org/docs/methods.pdf (accessed January 1, 2015).
30. Seaquist ER, Anderson J, Childs B, et al.: Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. J Clin Endocrinol Metab 2013;98:1845-1859.
31. Dungan K, Lyons S, Manu K, et al.: An individualized inpatient diabetes education and hospital transition program for poorly controlled hospitalized patients with diabetes. Endocr Pract 2014;20:1265-1273.
32. Hayes RP, Fitzgerald JT, Jacober SJ: Primary care physician beliefs about insulin initiation in patients with type 2 diabetes. Int J Clin Pract 2008;62:860-868.
33. Liu M, Sun LH, Liu G: Economic burden and economic risk of five major chronic diseases among Chinese urban residents [in Chinese]. Beijing Da Xue Xue Bao 2014;46:782-789.
34. Spijkerman AMW, Henry RMA, Dekker JM, et al.: Prevalence of macrovascular disease amongst type 2 diabetic patients detected by targeted screening and patients newly diagnosed in general practice: the Hoorn Screening Study. J Intern Med 2004;256:429-436.
35. Peyrot M, Rubin RR, Lauritzen T, et al.: Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005;28:2673-2679.
36. Davidson MB, Raskin P, Tanenberg RJ, et al.: A stepwise approach to insulin therapy in patients with type 2 diabetes mellitus and basal insulin treatment failure. Endocr Pract 2011;17:395-403.
37. Larkin ME, Capasso VA, Chen CL, et al.: Measuring psychological insulin resistance: barriers to insulin use. Diabetes Educ 2008;34:511-517.
38. Xiong Z, Yuan L, Guo X, et al.: Rejection of insulin therapy among patients with type 2 diabetes in China: reasons and recommendations. Chin Med J (Engl) 2014;127:3530-3536.
39. Ziemer DC, Miller CD, Rhee MK, et al.: Clinical inertia contributes to poor diabetes control in a primary care setting. Diabetes Educ 2005;31:564-571.
40. Ji L, Lu J, Weng J, et al.: China type 2 diabetes treatment status survey of treatment pattern of oral drugs users. J Diabetes 2015;7:166-173.
41. Patel A, MacMahon S, Chalmers J, et al.: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572.